Screener
Insulet PODD Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $801.7M+23.5% | $761.7M+33.9% | $783.8M+31.2% | $706.3M+29.9% | $649.1M+32.9% | ||
| $239.1M+21.4% | $232.7M+45.5% | $215.2M+29.2% | $196.2M+17.6% | $196.9M+24.9% | ||
| $562.6M+24.4% | $529M+29.3% | $568.6M+32.0% | $510.1M+35.3% | $452.2M+36.7% | ||
| 70.2%+0.5pp | 69.4%-2.4pp | 72.5%+0.4pp | 72.2%+2.9pp | 69.7%+1.9pp | ||
| $88.1M+20.0% | $89.7M+50.5% | $90.9M+50.0% | $77.2M+40.6% | $73.4M+36.2% | ||
| $344.8M+33.8% | $317.2M+21.7% | $331.4M+27.0% | $315.2M+34.6% | $257.7M+15.8% | ||
| $129.7M+7.1% | $122.1M+37.5% | $146.3M+33.9% | $117.7M+33.6% | $121.1M+122% | ||
| 16.2%-2.5pp | 16%+0.4pp | 18.7%+0.4pp | 16.7%+0.5pp | 18.7%+7.5pp | ||
| $13.5M-31.1% | $14.7M+59.8% | $14.9M+73.3% | $15.6M+25.8% | $19.6M+78.2% | ||
| -$1.1M-185% | $700K+132% | $3.1M— | $12.1M+456% | $1.3M+172% | ||
| $118.7M+318% | $113M+134% | $140.2M+25.9% | $122.8M+48.1% | $28.4M-44.4% | ||
| $23.7M+302% | $21.9M+72.4% | $38.5M— | $35.2M+552% | $5.9M+104% | ||
| $95M+322% | $91.1M+157% | $101.6M+0.9% | $87.6M+13.0% | $22.5M-88.1% | ||
| 11.8%+8.4pp | 12%+5.7pp | 13%-3.9pp | 12.4%-1.8pp | 3.5%-35.1pp | ||
| $1.37+328% | $1.30+160% | $1.43+3.6% | $1.24+14.8% | $0.32-87.6% | ||
| $156.4M+9.1% | $148.3M+34.2% | $170.7M+30.5% | $139.7M+27.7% | $143.4M+94.6% | ||
| 19.5%-2.6pp | 19.5%0.0pp | 21.8%-0.1pp | 19.8%-0.3pp | 22.1%+7.0pp | ||
| $129.7M+7.1% | $122.1M+37.5% | $146.3M+33.9% | $117.7M+33.6% | $121.1M+122% |
FAQ
- What is Insulet's revenue?
- Insulet (PODD) generated $3.1B in revenue over the trailing twelve months, up 29.4% year over year.
- Is Insulet profitable?
- Insulet reported $375.3M in net income over the trailing twelve months, a 12.3% net margin.
- What are Insulet's profit margins?
- Gross margin is 71.1% and operating margin is 16.9%, with a 12.3% net margin.
- What is Insulet's earnings per share?
- Insulet's diluted EPS over the trailing twelve months is $5.34.
- Where does Insulet's income statement data come from?
- Every line is extracted from Insulet's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
